RESEARCH ARTICLE

Attitudes of healthy volunteers to genetic testing in phase 1 clinical trials [version 1; peer review: 2 approved]

Sebastian Levesque1,2, Thomas M. Polasek1,3,4, Eric Haan5,6, Sepehr Shakib1,2

1Department of Clinical Pharmacology, Royal Adelaide Hospital, Adelaide, South Australia, 5000, Australia
2Discipline of Pharmacology, The University of Adelaide, Adelaide, South Australia, 5000, Australia
3Centre for Medicines Use and Safety, Monash University, Melbourne, Victoria, 3052, Australia
4Certara, Princeton, New Jersey, 08540, USA
5Adult Genetics Unit, Royal Adelaide Hospital, Adelaide, South Australia, 5000, Australia
6Faculty of Health and Medical Science, The University of Adelaide, Adelaide, South Australia, 5000, Australia

First published: 30 Mar 2021, 10:259
https://doi.org/10.12688/f1000research.26828.1
Latest published: 30 Mar 2021, 10:259
https://doi.org/10.12688/f1000research.26828.1

Abstract

Background: Genetic testing in clinical trials introduces several ethical and logistical issues to discuss with potential participants when taking informed consent. The aim of this study was to explore the attitudes of healthy volunteers in phase 1 studies to the topics of genetic security, genetic privacy and incidental genetic findings.

Methods: Healthy volunteers presenting for screening appointments at a phase 1 clinical trial unit (CMAX Clinical Research, Adelaide, Australia) took an anonymous paper survey about genetic testing.

Results: There were 275 respondents to the survey. The mean age was 27 years (range 18-73); 54% were male and 53% were of North/Western European ethnicity. Just over half the healthy volunteers thought genetic security (56%) and genetic privacy (57%) were “important” or “very important”. However, the security of their genetic information was ranked less important than other personal information, including mobile phone number, internet browser search history and email address. Two-thirds of respondents would trade genetic privacy for re-identifiability if information relevant to their health were discovered by genetic testing. Healthy volunteers favoured the return of incidental genetic findings (90% indicated this was “important” or “very important”). A level of risk (10 to 90%) for developing a serious medical condition that would “trigger” the return of incidental genetic findings to participants was not identified.

Conclusions: Healthy volunteers screening for phase 1 clinical trials have mixed views about the importance of genetic security and genetic privacy, but they strongly favour the return of incidental genetic findings that could affect their health. These issues should be discussed with potential participants during informed consent for phase 1 clinical trials with genetic testing.
Keywords
phase 1, genetics, healthy volunteers, informed consent, pharmacogenetics
Introduction
Genetic testing during clinical drug trials can determine whether genetics influences how patients respond to drug therapy. 1,2 Increasingly, genetic information is collected from healthy volunteers during phase 1 clinical studies to identify factors that inform later stages of drug development, including dosing strategies, patient selection, and the potential role of biomarkers to monitor drug responses. 3 Genetic testing in clinical trials introduces several ethical and logistical issues for participation, including concerns about genetic security and genetic privacy and how investigators should proceed with incidental genetic findings. Genetic security is the secure storage of genetic data and material. Clinical trial facilities and pharmaceutical companies must store these data for at least 15 years, 4 so there is potential for misappropriation, release and misuse during this time. Genetic privacy is the protection of a person’s genetic information so they cannot be identified without knowledge and consent. 4 Incidental genetic findings are results unrelated to the initial reason for genetic testing. These results may have implications for the current and future health and wellbeing of participants e.g., if genetic results influence susceptibility to disease or raise questions about ancestry or parentage. In Australia, the National Health and Medical Research Council (NHMRC) has recommendations on how to address genetic topics in clinical drug trials. 3 For example, a separate participant information sheet and consent form (PICF) for the genetic component of studies should be used to discuss the nature of the genetic testing and its consequences for participants.

The attitudes of patients and the public to genetic testing in clinical trials have been explored in a very limited number of previous studies. These two groups generally favour the return of incidental genetic findings, 5,6 but sometimes express concerns regarding genetic privacy and security, fearing disclosure of genetic information and widespread data sharing and misuse. 8,9 There are no comparable data on these genetic topics for healthy volunteers. Given that healthy volunteers and patients are motivated differently for clinical trial participation, 10,11 for example, healthy volunteers primarily focus on financial remuneration whilst patients do not, differences in attitudes towards genetic testing between the groups may be expected. Thus, the aim of this study was to explore the attitudes of healthy volunteers in phase 1 studies to the issues of genetic security, genetic privacy and the return of incidental genetic findings.

Methods
Study design
Potential participants being screened for studies at a clinical trial facility (CMAX Clinical Research Pty Ltd, Adelaide, Australia) were questioned about their attitudes to genetic testing using a paper survey (May to September 2019). No formal sample size was set, with as many potential participants approached during the study period as possible. The survey was de-identified and no personal information was collected apart from demographics. No potential biases were considered to influence participation and therefore the inclusion criteria were kept simple: participants were eligible if they were presenting for a healthy volunteer clinical drug study, were ≥ 18 years of age, and had sufficient English to allow informed consent and to answer the survey. There were no further inclusion or exclusion criteria. Informed consent was obtained by the lead author (S.L.) and participants completed the survey independently in the waiting room. The Human Research Ethics Committee at the University of Adelaide approved the study (H-2019-085).

Surveys
Surveys were written by the authors to investigate attitudes towards genetic security, genetic privacy and incidental genetic findings. Questions were written in non-technical language to maximise readability and understanding. No formal validation or piloting of the survey was conducted prior to enrolment of the first participant. There were two iterations of the survey: an initial version (1st survey) involving Q1-6 and then an updated version (2nd survey) that included three additional questions (Q7-9) (see extended data 12). Several question formats were used. A 5-point Likert scale included the options “very unimportant”, “unimportant”, “neutral”, “important” or “very important”. Other questions used a rank scale method (1-5, with 1 being the least important and 5 being the most important), and in the case of ties, a mean rank was ascribed to the responses. Polar responses (yes/no) were used for statements regarding incidental genetic findings. The final question format was a visual analogue scale to investigate attitudes towards genetic privacy. The demographic data collected were age, ethnicity (2nd version of the survey only), level of education, and the number of clinical trials undertaken previously at CMAX Clinical Research. The definitions of ethnicity were those used by the Australian Standard of Classification of Ethnic and Cultural Groups. 13

Data analysis
Data from paper surveys were transcribed electronically and analysed using SPSS v25 (IBM corporation, Armonk, NY). Some responses were dichotomised as “favoured” (comprising the responses “important” and “very important”) or “not favoured” (comprising the responses “very unimportant”, “unimportant” and “neutral”). After analysis of the first 190 surveys, an amended survey was created which included three new questions. These questions created scenarios to
discern the motivations for some responses. A sample size of 300 was calculated to result in a 95% confidence interval of 5-10% for a range of proportions between 30%-70% for each question. Potential statistically significant relationships between responses and demographics were examined. Kruskal-Wallis tests were performed for any relationships with age, number of previous CMAX studies, ethnicity, and education. Mann-Whitney U-tests were performed for any relationships with gender. Statistical significance was set at p < 0.05.

**Results**

**Demographics**

Table 1 shows the demographic results of the study. There were 275 respondents who completed both surveys (85.8% participation) – 189 for the first and 85 for the second iteration. The mean age was 27 years (range 18-73 years); 54% were male, 55% completed high school as their highest form of education, 62% had not undertaken a clinical trial at CMAX Clinical Research previously, and 53% were of North/Western European ethnicity (Table 1).

Genetic security

Just over half the participants had a favourable attitude towards the importance of genetic security (56%) (Table 2 and Figure 1A). The favourable response was significantly associated with younger age (p=0.017) and the median age of favoured responses was 26 years. When participants were asked to rank the security of their genetic information against other personal identifying information, genetics had a similar mean rank to medical history, and was ranked less important than the other personal information such as mobile phone number, internet browser search history and email address (Figure 1B). There were no significant associations between this ranking question and demographics (Table 2).

Genetic privacy

More than half the participants had a favourable attitude towards the importance of genetic privacy (57%) (Table 2 and Figure 2A). No demographic factors were associated with responses to this question. When choosing between genetic privacy and re-identifiability, most respondents (67%) chose an option in the re-identifiability portion of the visual analogue scale (Figure 2B). Women were more likely to prefer re-identifiability than men (median on response scale of 0.70 versus 0.47, p=0.033), but no other statistical relationships to demographics were found (Table 3).

Incidental genetic findings

Participants strongly preferred the return of incidental genetic findings (90% favoured) and wanted this information included in PICFs (87% favoured) (Table 2) (Figure 3A). Both questions were not associated with any statistically
significant relationships to demographics. Respondents also preferred the return of incidental genetic findings for several cancer scenarios with varying hypothetical risks and treatability, but they were slightly less interested if the risk was very low and the cancer was untreatable (Figure 3B). When participants were asked to choose a risk for a specific disease that should trigger the return of incidental genetic findings, answers were similarly divided across all levels of risk (10-90%). The three most popular answers were for the options of 90% risk for developing a disease, with cancer > heart disease > neurodegeneration (Figure 3C). Older participants were more likely to select higher risk of disease to trigger the return of incidental genetic findings, whereas respondents with more clinical trial experience studies wanted information provided at lower levels of risks (Table 3). About 90% of participants wanted information provided to them in the future if sample re-analysis or new genetic discoveries could influence their health and wellbeing (Table 2).

Table 2. Dichotomised results for Likert scale questions.

| Question                                                                 | n   | Favour          | Not favoured    |
|-------------------------------------------------------------------------|-----|-----------------|-----------------|
| Is genetic security important to you?                                   | 274 | 152(55.5%)      | 122(44.5%)      |
| Is genetic privacy important to you?                                    | 274 | 156(56.9%)      | 118(43.1%)      |
| Do you think incidental genetic findings should be mentioned in the information sheet? | 275 | 239(86.9%)      | 36(13.1%)       |
| Do you think it is important to be informed of any incidental genetic findings? | 275 | 248(90.2%)      | 27(9.8%)        |
| If your genetic information is re-analysed, would you want to be informed of these results? | 190 | 169(88.9%)      | 21(11.1%)       |

Figure 1. Attitudes toward the importance of genetic security (A) and the level of importance of (Scale 1-5) of personal identifying information (B).

Figure 2. Attitudes towards the importance of genetic privacy (A) and preference for genetic privacy versus re-identifiability, where −1 is total genetic privacy and 1 is total re-identifiability (B).
Discussion

This is the first study to report the attitudes of healthy volunteers to genetic testing in phase 1 clinical trials. These attitudes are important to understand given the rise of genetic testing in early drug development and the unique ethical and practical aspects of testing healthy volunteers who typically have few interactions with healthcare providers. Here, the focus was the genetic testing issues previously explored in limited studies with patients and the public – genetic security, genetic privacy, and the return of incidental genetic findings.6–11

There was relative indifference towards genetic security, with healthy volunteers ranking the importance of this topic lower than for other personal information. Indeed, mobile phone number and email address are provided to the clinical trial site during screening, so for genetic security to rank lower than these two pieces of information emphasises the relative indifference to the topic. This is similar to limited data in patients, with only 35% of potential biobank participants and just one patient in a focus group of 15 with epilepsy expressing concerns about genetic security.6,14

Table 3. Statistical analyses.

| Question                                                                 | Age       | Gender | Education | Number of previous studies at CMAX Clinical Research | Ethnicity |
|--------------------------------------------------------------------------|-----------|--------|-----------|------------------------------------------------------|-----------|
| Is genetic security important to you?                                   | p = 0.017| ns     | ns        | ns                                                   | ns        |
| Is genetic privacy important to you?                                    | ns        | ns     | ns        | ns                                                   | ns        |
| Do you think incidental findings should be mentioned in the information sheet? | ns        | ns     | ns        | ns                                                   | ns        |
| Do you think it is important to be informed of any incidental findings? | ns        | ns     | ns        | ns                                                   | ns        |
| If your genetic information is re-analysed, how important is it you are informed of these results? | ns        | ns     | ns        | ns                                                   | na        |
| What risk level would you accept for the following diseases?            |           |        |           |                                                      |           |
| Cancer                                                                   | p = 0.035 | ns     | ns        | p = 0.006                                           | ns        |
| Heart disease                                                            | p = 0.004 | ns     | ns        | p = 0.010                                           | ns        |
| Neurodegeneration                                                        | p = 0.001 | ns     | ns        | p = 0.015                                           | ns        |
| Would you trade the privacy of your genetic information for re-identifiability in a future outcome? | ns        |        |           |                                                      | ns        |
| Rank your personal information in terms of how important the security of the information is to you | ns        | ns     | ns        | ns                                                   | ns        |
| If you had a 50% risk of developing a potentially fatal form of untreatable cancer would you want results returned? | ns        | ns     | ns        | ns                                                   | ns        |

ns, not statistically significant; na, not applicable.
Regarding genetic privacy, healthy volunteers also held mixed opinions, with just over half considering it “important” or “very important”. This is comparable to a survey of 4659 US adults from the public, in which 44% would protect genetic test results, whereas the others were happy to share their genetic data with researchers. Additionally, a survey assessing the views of 57 patients to pharmacogenomic testing showed that approximately 40% expressed concerns about privacy. When asked whether they would trade privacy for re-identifiability in the future, respondents to our survey overwhelmingly favoured re-identifiability of their genetic information. Taken together, these findings support clinical research governance that de-identifies genetic information to maintain privacy, but with mechanisms in place to re-identify that information if asked by clinical trial participants.

The healthy volunteers wanted incidental genetic findings returned to them, and this applied to a range of hypothetical clinical scenarios with varying degrees of disease risk. Older participants and those with more clinical trial experience

**Figure 3.** Attitudes towards the importance of returning incidental genetic findings (A), various cancer scenarios that could influence the return of incidental genetic findings (B), and the degree of risk that could influence the return of incidental genetic findings (C).
accepted higher disease risk before triggering the return of such information. Exactly why these two groups indicated higher disease risk is unclear, but it may be simply related to life experience and greater acceptance of the unknown. The majority of oncology patients in a previous study also favoured the return of incidental findings, even if they constituted “bad news”, such as high risk of developing an untreatable cancer. Studies of the public indicate the same (4961 participants), with “treatability” being an important consideration and with 98% in favour of findings being returned for “a serious disease that is life threatening but could be prevented”. Together with the results in healthy volunteers, these data suggest that everyone should be asked about their wishes for the return of incidental genetic findings when being screened for clinical trials.

There are several limitations of the study. First, it was conducted at one site, so care is required in extrapolating the results to other phase I clinical units with significantly different volunteer demographics. Second, the survey was offered opportunistically to all people in the waiting room, independent of the type of clinical trial screening. It is possible that attitudes to genetic testing are different between healthy volunteers being screened for clinical trials with genetic testing and those being screened for clinical trials without genetic testing. Third, the study did not assess baseline “genetic literacy”, so misunderstanding of questions is possible, particularly the conceptually more difficult questions related to disease risks. Lastly, the study was not designed to capture the nuances of genetic testing because the topic is too broad and complex to be condensed into a short survey e.g., the specifics of testing.

In conclusion, healthy volunteers who are screening for phase I clinical trials have mixed views about the importance of genetic security and genetic privacy, but they strongly favour the return of incidental genetic findings that could affect their health. These issues should be discussed with potential participants during informed consent for phase I clinical trials with genetic testing.

Data availability
Underlying data
Figshare: Attitudes to Genetic Testing in Phase 1_Survey Data. https://doi.org/10.6084/m9.figshare.14204507.v1.16

Figshare: Untitled Attitudes to Genetic Testing in Phase 1_Amalgamated Survey Data. https://doi.org/10.6084/m9.figshare.14204516.v1.17

Extended data
Figshare: Attitudes to genetic testing in phase 1 survey questions. https://doi.org/10.6084/m9.figshare.14182898.v1.12

This project contains the following extended data:

- A supplementary figure showing all the survey questions used in the study.

Data are available under the terms of the Creative Commons Attribution 4.0 International license (CC-BY 4.0).

Acknowledgements
We thank the staff at CMAX Clinical Research Ltd Pty for assisting with this study.

Competing interests
No competing interests were disclosed.

References
1. Burt T, Dhillon S: Pharmacogenomics in early-phase clinical development. Pharmacogenomics J. 2013; 14(9): 1085-1097. PubMed Abstract | Publisher Full Text | Free Full Text
2. ICH: E15 Definitions for Genomic Biomarkers, Pharmacogenomics, Pharmacogenetics, Genomic Data and Sample Coding Categories. 2008.
3. National Health and Medical Research Council Australian Research Council and Universities Australia: Management of Data and Information in Research: A guide supporting the Australian Code for the Responsible Conduct of Research. 2019.
4. McGuire AL, Fisher R, Cusenza P, et al.: Confidentiality, privacy, and security of genetic and genomic test information in electronic health records: points to consider. Genet Med. 2008; 10(7): 495–499. PubMed Abstract | Publisher Full Text
5. National Health and Medical Research Council: Principles for the translation of 'omics'– based tests from discovery to health care. 2015.
6. Gray SW, Park ER, Najita J, et al.: Oncologists’ and cancer patients’ views on whole-exome sequencing and incidental findings: results from the CanSeq study. *Genet Med.* 2016; 18(10): 1011–1019. PubMed Abstract | Publisher Full Text | Free Full Text

7. Middleton A, Morley KI, Bragin E, et al.: Attitudes of nearly 7000 health professionals, genomic researchers and publics toward the return of incidental results from sequencing research. *Eur J Hum Genet.* 2016; 24(1): 21–29. PubMed Abstract | Publisher Full Text | Free Full Text

8. Rahm AK, Wrenn M, Carroll NM, et al.: Biobanking for research: a survey of patient population attitudes and understanding. *J Community Genet.* 2013; 4(4): 445–450. PubMed Abstract | Publisher Full Text | Free Full Text

9. Lemke AA, Hulick PJ, Wake DT, et al.: Patient perspectives following pharmacogenomics results disclosure in an integrated health system. *Pharmacogenomics J.* 2018; 19(4): 321–331. PubMed Abstract | Publisher Full Text

10. Facio FM, Brooks S, Loewenstein J, et al.: Motivators for participation in a whole-genome sequencing study: implications for translational genomics research. *Eur J Hum Genet.* 2011; 19(12): 1213–1217. PubMed Abstract | Publisher Full Text | Free Full Text

11. Treloar SA, Morley KI, Taylor SD, et al.: Why do they do it? A pilot study towards understanding participant motivation and experience in a large genetic epidemiological study of endometriosis. *Community Genet.* 2007; 10(2): 61–71. PubMed Abstract | Publisher Full Text

12. Polasek TM: Attitudes to genetic testing in phase 1 survey questions. *figshare.* Figure. 2021

13. Australian Bureau of Statistics: *Australian Standard Classification of Cultural and Ethnic Groups.* 2016.

14. McGuire AL, Hamilton JA, Lunsford R, et al.: DNA data sharing: research participants’ perspectives. *Genet Med.* 2008; 10(1): 46–53. PubMed Abstract | Publisher Full Text | Free Full Text

15. Kaufman DJ, Murphy-Bollinger J, Scott J, et al.: Public opinion about the importance of privacy in biobank research. *Am J Hum Genet.* 2009; 85(5): 643–654. PubMed Abstract | Publisher Full Text | Free Full Text

16. Polasek TM: Attitudes to Genetic Testing in Phase 1 Survey Data. *figshare.* Dataset. 2021. Publisher Full Text

17. Polasek TM: Attitudes to Genetic Testing in Phase 1 Amalgamated Survey Data. *figshare.* Dataset. 2021. Publisher Full Text
Open Peer Review

Current Peer Review Status:  ✔️  ✔️

Version 1

Reviewer Report 24 January 2022

https://doi.org/10.5256/f1000research.29624.r119428

© 2022 Aldous C. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Colleen Aldous

College of Health Sciences, Nelson R. Mandela School of Clinical Medicine, University of KwaZulu-Natal, Durban, South Africa

Healthy participants were selected to complete an unpiloted and non-validated questionnaire which investigated attitudes to genetic information security, privacy and the return of incidental genetic findings. Ethics permission was provided and informed consent was noted. This is a descriptive study and the data is presented appropriately. The Lickert scale data is converted into a form which can be statistically compared. The findings are clearly summarised. There is a conclusion based on the data that the return of incidental genetic findings should be addressed. The limitations of the study are stated.

Queries:
○ A sample size of 300 participants had been calculated, however the final number reported on was 275. Could the authors please clarify this point?

○ Ethnicity is addressed but seems not to have much of a role in the answering of the research questions. In the abstract the reader is left questioning the other ethnicities after only North/Western European ethnicity is mentioned. In Table 1 the ethnicity of only 84 participants appears to have been reported. I would suggest that the authors state that ethnicity, for this study, was not addressed. This study raises further questions for future studies.

Is the work clearly and accurately presented and does it cite the current literature?
Partly

Is the study design appropriate and is the work technically sound?
Partly

Are sufficient details of methods and analysis provided to allow replication by others?
Yes
If applicable, is the statistical analysis and its interpretation appropriate?
Yes

Are all the source data underlying the results available to ensure full reproducibility?
Yes

Are the conclusions drawn adequately supported by the results?
Yes

**Competing Interests:** No competing interests were disclosed.

**Reviewer Expertise:** Healthcare research with a special interest in rare and congenital disorders.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.
There appears to be an inconsistency with the previous paragraph under ‘Data Analysis’ that says after analysis of the first 190 surveys, a second iteration was created. Were 190 survey of the first iteration started and only 189 completed?

**Is the work clearly and accurately presented and does it cite the current literature?**
Yes

**Is the study design appropriate and is the work technically sound?**
Yes

**Are sufficient details of methods and analysis provided to allow replication by others?**
Yes

**If applicable, is the statistical analysis and its interpretation appropriate?**
Yes

**Are all the source data underlying the results available to ensure full reproducibility?**
Yes

**Are the conclusions drawn adequately supported by the results?**
Yes

*Competing Interests:* No competing interests were disclosed.

*Reviewer Expertise:* Genetics, neuroscience, cell biology, major depressive disorder and pharmacogenomics.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.
The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com